The current medications used for AD treatment primarily target downstream factors, such as neurotransmitter imbalances, rather than directly addressing the accumulation of tau proteins and beta-amyloid, inflammation, and OS, which are hypothesized to drive the progression of AD (Santos, Chaves, and Várnagy, 2021). This evidence concerns the gene MAPT and Alzheimer disease.